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Abstract: 
 
Background - Brugada syndrome (BrS) is characterized by the type 1 Brugada ECG pattern. 
Pathogenic rare variants in SCN5A (mutations) are identified in 20% of BrS families in whom 
incomplete penetrance and genotype-negative phenotype-positive individuals are observed. 
E1784K-SCN5A is the most common SCN5A mutation identified. We determined the association 
of a BrS genetic risk score (BrS-GRS) and SCN5A mutation type on BrS phenotype in BrS 
families with SCN5A mutations. 
Methods - Subjects with a spontaneous type 1 pattern or positive/negative drug challenge from 
cohorts harboring SCN5A mutations were recruited from 16 centers (n=312). Single nucleotide 
polymorphisms (SNP) previously associated with BrS at genome-wide significance were studied 
in both cohorts: rs11708996, rs10428132 and rs9388451. An additive linear genetic model for 
the BrS-GRS was assumed (6 SNP risk alleles).   
Results - In the total population (n=312), BrS-GRS ≥4 risk alleles yielded an odds ratio (OR) of 
4.15 for BrS phenotype (95%CI:1.45-11.85, p=0.0078). Amongst SCN5A-positive individuals 
(n=258), BrS-GRS ≥4 risk alleles yielded an odds ratio (OR) of 2.35 (95%CI:0.89-6.22, 
p=0.0846). In SCN5A-negative relatives (n=54), BrS-GRS ≥4 alleles yielded and OR of 22.29 
(95%CI:1.84-269.30, p=0.0146). Among E1784K-SCN5A positive family members (n=79), 
hosting ≥4 risk alleles gave an OR=5.12 (95%CI:1.93-13.62, p=0.0011).  
Conclusions - Common genetic variation is associated with variable expressivity of BrS 
phenotype in SCN5A families, explaining in part incomplete penetrance and genotype-negative 
phenotype-positive individuals. SCN5A mutation genotype and a BrS-GRS associate with BrS 
phenotype but the strength of association varies according to presence of a SCN5A mutation and 
severity of loss of function. 
 
 
 
Key words: Brugada syndrome; genetics, human; risk score; SCN5A; single nucleotide 
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Nonstandard Abbreviations and Acronyms 
ACMG American College of Medical Genetics 
BrS  Brugada syndrome 
BrS-GRS Brugada syndrome genetic risk score 
ECG  Electrocardiogram 
GEE  Generalised estimating equation 
GWAS Genome wide association study 
ICC  Inherited cardiac conditions 
KASP  Kompetitive Allele Specific PCR 
OR  Odds ratio 
PCR  Polymerase chain reaction 
SD  Standard deviation 
SNP  Single nucleotide polymorphism 
 
 
 
Introduction  
Brugada syndrome (BrS) is characterized by the type 1 Brugada ECG pattern, present either 
spontaneously or after provocation with a sodium channel blocking agent.1 Pathogenic rare 
variants (mutations) in the SCN5A gene, encoding the Nav1.5 sodium channel, are identified in 
20% of cases.2,3 Incomplete penetrance and variable expression is common in BrS pedigrees with 
SCN5A mutations, suggesting a complex inheritance wherein other genetic variants may affect 
the phenotype.2 Genotype-negative individuals from SCN5A-positive pedigrees have shown the 
type 1 Brugada ECG pattern.2 Furthermore, common genetic variation has been associated with 
BrS in probands, independent of SCN5A status.4  
 The E1784K-SCN5A mutation (c.5350G>A; ClinVar ID: 9377) is the most common 
SCN5A mutation identified in BrS, identified in 3% of unrelated BrS cases3,5 and is absent in the 
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gnomAD database. Furthermore, E1784K-SCN5A exhibits incomplete penetrance and can 
manifest as a mixed clinical phenotype of long QT syndrome and/or BrS, even amongst affected 
individuals from the same pedigree.6,7 These properties make E1784K-SCN5A an optimal target 
for studying potential genetic modifiers.8 
 We hypothesized that common genetic variation previously associated with BrS4, and a 
genetic risk score derived thereof (BrS-GRS), is associated with a type 1 Brugada ECG pattern in 
genotype-positive individuals from BrS families hosting SCN5A mutations as well as in 
genotype-negative relatives. We then explored the effects of SCN5A mutation type on the 
likelihood of a type 1 Brugada ECG pattern. 
 
Methods 
The data that support the findings of this study are available from the corresponding author upon 
reasonable request. IRB approval was obtained, according to the guidelines noted in Instructions 
to Authors. The full methods are available as supplemental data. 
 
Results 
Clinical characteristics  
The total cohort comprised of 312 individuals from families harboring SCN5A mutations. The 
individuals that fulfilled inclusion criteria had the presence or absence of the BrS phenotype 
definitively established and had undergone complete SNP genotyping (Figure 1). These 312 
individuals were recruited from 137 families. The median family size was 1 (Q1-Q3: 1-2); four 
families had between 10 and 20 individuals and a single family contributed 31 individuals. 
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Figure 1 illustrates the breakdown of included cases according to SCN5A genotype and mutation 
type.  
Clinical characteristics are described and compared in Table 1. Subjects hosting SCN5A-
E1784K, when compared to individuals harboring loss-of-function mutations causing 
haploinsufficiency and other missense SCN5A mutations, were younger and more likely to be 
female. As would be expected when comparing individuals with an overlap syndrome to those 
with conduction disease, they exhibited longer QT intervals and shorter PR intervals and QRS 
durations on their presenting ECGs.  
Seventy-nine individuals were E1784K-SCN5A positive. Fifty-seven (72%) with 
E1784K-SCN5A had BrS phenotype (10 spontaneous; 47 drug-induced). Amongst the 179 
individuals harboring loss-of-function mutations causing haploinsufficiency and other missense 
SCN5A mutations, 164 (92%) had BrS phenotype (78 spontaneous; 61 drug-induced; 25 
unspecified). Importantly, 6/54 (17%) SCN5A negative subjects displayed a drug-induced BrS 
phenotype.  The associations of SCN5A mutation and/or BrS-GRS with the spontaneous BrS 
phenotype are similar to those described in both spontaneous and drug induced BrS combined, 
but were less accurate with higher p-values (data not shown). 
SCN5A mutation associations (Figure 2) 
Amongst SCN5A families the presence of an SCN5A mutation was associated with an odds ratio 
(OR) of 51.98 (95%CI:20.02-134.93, p<0.0001) for BrS phenotype. In all three SCN5A mutation 
type subgroups, i.e. E1784K-SCN5A, loss-of-function mutations causing haploinsufficiency and 
missense mutations other than E1784K-SCN5A, genotype positive patients were at an increased 
risk of BrS compared to genotype negative patients, but the odds ratios differed significantly 
(pinteraction=0.004) between the mutation types. 
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Amongst SCN5A genotype positive individuals only, both loss-of-function mutations causing 
haploinsufficiency and other missense mutations had an increased risk of BrS compared to 
E1784K-SCN5A with OR = 6.11 (95%CI:1.78-20.97, p=0.0040) and OR = 3.44 (95%CI:1.35- 
8.75, p=0.0095), respectively. 
Brugada Syndrome Genetic Risk Score 
The BrS-GRS was calculated for each subject in the total cohort as described. A weighted BrS-
GRS was also tested, but this did not outperform the non-weighted BrS-GRS (data not shown). 
Figure 3 shows the distribution of proportion of subjects according to numbers of risk alleles 
(range 0-6) for the total cohort and subsets of SCN5A mutations. In the total population, the odds 
ratio per allele was 1.46 (95%CI 1.11-1.94, p=0.0076) and individuals with a BrS-GRS ≥4 risk 
alleles had an OR=4.15 (95%CI 1.45-11.85, p=0.0078) for BrS phenotype compared to 
individuals with a GRS <4 risk alleles.  
The BrS-GRS effects per allele and ≥4 risk alleles appeared smaller in SCN5A genotype 
positives, but this was not significant (pinteraction = 0.090 and 0.076, respectively). Within SCN5A 
genotype positives only, the BrS-GRS effects per allele and ≥4 risk alleles were significantly 
different between mutation types (pinteraction = 0.0096 and <0.0001, respectively). 
SCN5A genotype-positive relatives (n=258) yielded an OR=1.25 (95%CI 0.92-1.71, 
p=0.1571) for BrS phenotype per risk allele. Individuals with a BrS-GRS ≥4 risk alleles had an 
OR=2.35 (95%CI:0.89-6.22, p=0.0846) for BrS phenotype compared to individuals with a GRS 
<4 risk alleles. SCN5A genotype-negative relatives (n=54) yielded an OR for BrS phenotype of 
2.71 per risk allele (95%CI 0.98-7.43, p=0.0535). SCN5A genotype-negative individuals with a 
BrS-GRS ≥4 risk alleles had an OR=22.29 (95%CI 1.84-269.30, p=0.0146) for BrS phenotype 
compared to individuals with a BrS-GRS <4 risk alleles (Figures 4 and 5).  
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SCN5A loss-of-function mutations causing haploinsufficiency 
For subjects hosting loss-of-function SCN5A mutations causing haploinsufficiency the 
association between the BrS-GRS and BrS phenotype appeared the strongest (OR per risk allele 
of 5.18; 95%CI:2.07-12.93, p=0.0004). Since there were no BrS negative cases that had more 
than 2 risk alleles, the OR of subjects with ≥4 risk alleles was infinite compared to subjects with 
<4 risk alleles (Figures 3, 4 and 5).  
SCN5A-E1784K 
When examining E1784K-SCN5A positive family members alone, a weaker BrS-GRS 
performance was found: OR=1.49 (95%CI 1.09-2.04, p=0.0135) per risk allele. Individuals with 
a BrS-GRS ≥4 risk alleles had an OR=5.12 (95%CI:1.93-13.62, p=0.0011) for BrS phenotype 
compared to individuals with a GRS <4 risk alleles (Figures 4 and 5). 
Other missense SCN5A mutations 
For individuals hosting other SCN5A mutations there was no statistically significant association 
between the BrS-GRS and BrS phenotype (OR per risk allele=0.88, 95%CI 0.58-1.32, 
p=0.5271). Subjects with ≥4 risk alleles had an OR=1.03 (95%CI:0.20-5.35, p=0.9705) for BrS 
phenotype compared to those with less than 4 risk alleles (Figures 4 and 5).  
 
Discussion 
Historically, BrS was considered an autosomal dominant monogenic disorder. In 2013, a 
common variant GWAS comparing index cases of BrS to healthy controls indicated association 
with common genetic variation, regardless of presence of an SCN5A mutation.4 While that work 
identified susceptibility loci, up to now, the variable expression of the BrS phenotype in 
members of families with SCN5A mutations has remained unexplained. Here, for the first time 
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we report that common genetic variation, in the form of a BrS-GRS, correlates with the BrS 
phenotype in individuals from families with SCN5A loss-of-function mutations causing 
haploinsufficiency and the recurrent mutation E1784K-SCN5A. Furthermore, our study extends 
beyond the findings of the original GWAS by emphasizing the role of common variation in 
expression of the BrS phenotype independent of the presence of an SCN5A mutation. The BrS-
GRS explained in part the variable expression of BrS phenotype in both SCN5A-positive and 
SCN5A-negative relatives. There was significant heterogeneity of the strength of association of 
different types of SCN5A mutation (loss-of-function causing haploinsufficiency, E1784K and 
other missense) and their associated BrS-GRS with BrS phenotype indicating a variable 
biological effect of common and rare variants on disease susceptibility. These findings support a 
complex polygenic architecture for BrS and are an important proof of principle in cardiac 
genetics. 
A BrS-GRS and variability in BrS phenotype within affected families 
We sought to investigate whether a BrS-GRS is associated with BrS phenotype. The score 
demonstrated association with BrS phenotype in pedigrees carrying pathogenic or likely 
pathogenic SCN5A variants, reflecting the cumulative effect of the three SNPs (six risk alleles) 
on BrS phenotype. The BrS-GRS was then tested separately in the subset of families harboring 
loss-of-function SCN5A mutations causing haploinsufficiency, detecting a strong effect size and 
a near infinite OR when harboring four or more risk alleles. This may reflect the small numbers 
of Brugada negative cases with loss-of-function mutations causing haploinsufficiency and that 
chromosome 3 risk alleles in trans with the mutant allele are more likely to have a more potent 
effect by further altering the expression of already haplo-insufficient wild-type SCN5A.  
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 Families with missense SCN5A mutations other than E1784K-SCN5A showed no 
significant associations with the BrS-GRS whilst the E1784K-SCN5A subset exhibited a 
significant association, albeit weaker than for loss-of-function mutations causing 
haploinsufficiency. The reasons for this difference are likely to be complex. Firstly, E1784K-
SCN5A is considered a relatively mild missense mutation in its biophysical and clinical 
consequences and showed lower penetrance in our study compared to other missense mutations 
(72% vs 90% respectively, Table 1).9 The association of the BrS-GRS may therefore reflect a 
greater impact of common variation in this setting. Secondly, the diversity of the other included 
missense SCN5A mutations may have led to a weaker power for evaluating the BrS-GRS 
compared to E1784K-SCN5A families. Each mutation is expected to have different severity of 
biophysical defects with the potential for variable effects of SNPs on the lesion. Furthermore, 
due to the small size and heterogeneity of the total cohort, there was insufficient power to 
analyze chromosomal phasing between SCN5A mutations and the SNPs of interest. The other 
missense SCN5A mutation group was therefore a less homogeneous group to test for associations 
than a large group of families with a single mutation such as E1784K-SCN5A. More 
homogeneous samples, particularly founder populations, may be more appropriate for future 
studies of how common variants modify phenotype. Interestingly in SCN5A genotype-negative 
relatives, the association of BrS-GRS ≥4 risk alleles with BrS phenotype was even more 
apparent. In fact, the OR was greater than that of E1784K-SCN5A in isolation. This supports a 
greater strength of association of common variation with the likelihood of BrS phenotype in the 
absence of a SCN5A mutation. 
 These results therefore reveal the potential for clinical utility of incorporating common 
genetic variation in the form of a genetic risk score in genetic diagnostics for rare disease. It is 
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expected, however, that additional SNPs underlie the complex genetic nature of BrS and a larger 
GWAS is needed to identify other common variants that could be incorporated to improve the 
power of an optimized BrS-GRS for diagnostic purposes. This will also require further 
investigation of greater numbers of relatives with integration of haplotype structure and detailed 
knowledge of SCN5A variants’ biophysical properties.  
Association of rare SCN5A variation with BrS phenotype and common variants 
While common variation in the form of a BrS-GRS has clear independent association with BrS 
phenotype, the strongest contribution comes from the presence of an SCN5A mutation. However, 
not all SCN5A BrS susceptibility mutations have comparable functional effects. The OR for the 
BrS phenotype associated with E1784K-SCN5A is significantly lower than for other missense 
SCN5A mutations but is greatest in loss-of-function mutations causing haploinsufficiency. 
Furthermore, the OR of the BrS-GRS for BrS phenotype varied according to SCN5A mutation 
and was strongest in genotype negative relatives. This suggests that there may be an interaction 
and synergy of common and rare variation affecting sodium channel function whereby a certain 
level of impairment is necessary to achieve a threshold where BrS phenotype can manifest. This 
further supports a polygenic genetic architecture underlying the condition.10  
Genotype-phenotype mismatch in BrS and its implications 
The proposed polygenic model of heritability in BrS may explain the paradox of clinically 
affected mutation-negative individuals in SCN5A families, first demonstrated by Probst et al.2 
Indeed, 12% of SCN5A-negative relatives showed a drug-induced BrS phenotype. Importantly, 
cascade genetic screening in SCN5A pedigrees can result in SCN5A genotype-negative relatives 
being discharged from further follow-up. A small proportion of these individuals may still be at 
risk of developing a BrS phenotype. Conversely, these findings also raise further questions about 
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the specificity of drug provocation tests for BrS in the absence of a gold standard test for the 
condition. The prevalence of the type 1 Brugada ECG pattern after drug provocation testing has 
already been shown to be much higher than expected (4%) in healthy controls.11 Indeed recent 
data have associated a similar BrS polygenic risk score with the ajmaline induced type 1 
pattern.12 The Shanghai consensus document downgraded the diagnostic certainty offered by 
such a result when found in isolation.13 The likelihood of a drug-induced type 1 Brugada ECG 
pattern indicating a diagnosis of BrS is considered greater, however, if an individual had a family 
history of premature autopsy negative SCD and/or BrS. The significance of a drug-induced type 
1 Brugada ECG pattern in SCN5A genotype-negative relatives is therefore uncertain in SCN5A 
BrS families. Other, as yet unknown, polygenic and acquired contributions to the risk of 
developing BrS phenotype may be present in these SCN5A genotype-negative relatives. 
BrS phenotype-positive SCN5A genotype-negative individuals may be identified due to 
clinical evaluation taking place either prior to genetic studies being available, or prior to 
determination of the pathogenicity of a detected rare SCN5A variant. There is insufficient follow-
up data available, however, in the literature to determine if these individuals subsequently 
develop arrhythmic events. In the meantime, these patients may be offered monitoring for 
evidence of evolving risk and lifestyle advice such as avoidance of prescription sodium channel 
blocking drugs, cocaine and alcohol intoxication, and treatment of fever.14 Asymptomatic 
SCN5A-negative relatives of autopsy-negative SCD victims, who go on to have a positive 
ajmaline test, have been managed with this strategy. During follow-up, a spontaneous type 1 
Brugada ECG pattern and/or clinically significant arrhythmic events developed in 17% of these 
individuals.15 This may be a worthwhile approach in BrS SCN5A family members, regardless of 
genotype status, although further prospective research will be required. 
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Future perspective: an optimized BrS-GRS 
There is already strong association of a BrS-GRS ≥4 risk alleles utilizing only three SNPs with 
BrS phenotype. We propose that an optimized BrS-GRS employing additional SNPs emerging 
from a larger GWAS could act as a complementary approach to quantifying the probability of 
developing BrS phenotype. Furthermore, incorporating phasing of SNPs could further refine the 
predictive accuracy of a BrS-GRS, especially in SCN5A families where SNPs in trans to the 
SCN5A mutant allele would be expected to have more pronounced effects than SNPs in cis. An 
optimized and validated GRS may therefore aid decision-making over follow-up in SCN5A 
families and determining whether preventative and monitoring strategies for BrS should be 
instituted.1,13 A GRS-based approach may even replace the unnecessary use of drug challenge 
and form part of clinical genetic testing in BrS.   
Limitations  
BrS phenotype was defined in accordance with the 2013 HRS/EHRA/APHRS guidelines. Other 
guidelines have been proposed due to concerns over the specificity of the sodium channel 
blocker-induced BrS phenotype.1,13,15 These guidelines maintain the same definition of the type 1 
Brugada ECG pattern and give extra weight to a family history of BrS. We therefore used the 
same ECG definition for BrS phenotype in this study. We also treated spontaneous and drug-
induced BrS phenotype as one group for analysis purposes. This was due to low numbers, the 
similarity of findings in spontaneous BrS (data not shown) as well as the consistency of the 
association demonstrated by the BrS GWAS regardless of whether the phenotype was drug-
induced or spontaneous.4   
 A smaller proportion of the SCN5A genotype-negative cases underwent sodium channel 
blocker challenge, probably reflecting variation in local clinical practice. Furthermore, only a 
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relatively small proportion of SCN5A genotype-positive relatives were found to be BrS 
phenotype-negative after drug challenge. Both factors likely weakened the power to detect 
associations. 
 Due to the heterogeneity of the total cohort, there was insufficient power to analyze 
chromosomal phasing between the SCN5A mutations and the SNPs of interest at this 
chromosomal locus - rs11708996 (SCN5A) and rs10428132 (SCN10A) - and therefore SNP 
interactions. These potential interactions may explain why the weighted model for the BrS-GRS 
did not show additional significance over the additive model. Furthermore, families of Japanese 
and other non-Caucasian ancestry were included but due to small numbers could not be analysed 
separately. This was offset, however, by the three SNPs used to create the BrS-GRS having been 
replicated in Japanese BrS cases16. 
Conclusions 
Common genetic variation explains in part, the variable expression of BrS phenotype in families 
with sodium channel disease. Association of common variants was cumulative leading to a BrS-
GRS associated with BrS phenotype in both genotype positive and negative subjects i.e. 
independent of the presence of an SCN5A mutation. SCN5A mutations and the BrS-GRS also 
show differing effect sizes on BrS phenotype according to variant type, further confirming a 
complex polygenic architecture underlying BrS. These findings have important implications in 
BrS SCN5A families where a SCN5A-negative relative may still develop a BrS phenotype. 
Further work is required to elucidate other genetic factors to develop an optimized BrS-GRS that 
may become a surrogate marker for BrS phenotype in SCN5A families, form part of clinical 
genetic testing, obviate drug provocation testing and guide follow-up. 
 
Acknowledgments: In memory of our dear colleague and friend Velislav Batchvarov. 
D
ow
nloaded from
 http://ahajournals.org by on N
ovem
ber 17, 2020
DOI: 10.1161/CIRCGEN.120.002911 
 
14 
This article is published in its accepted form; it has not been copyedited and has not appeared in an issue of the journal. 
Preparation for inclusion in an issue of Circulation: Genomic and Precision Medicine involves copyediting, typesetting, 
proofreading, and author review, which may lead to differences between this accepted version of the manuscript and the 
final, published version. 
Sources of Funding: This work was supported by James Lancaster Memorial Fund sponsored 
by McColl’s RG Ltd.  YDW and ERB acknowledge funding and ongoing support from the 
James Lancaster Memorial Fund sponsored by McColl’s RG Ltd. YDW had received support 
through an Academic Clinical Fellowship from the National Institute of Health Research. ERB is 
supported by the Higher Education Funding Council for England and the British Heart 
Foundation (BHF). ERB, MM, HR, MP and SS acknowledge support from Cardiac Risk in the 
Young. ERB and HR acknowledge support from BHF Project Grant PG/15/107/31908 and BHF 
Clinical Research Training Fellowship FS/11/71/28918 respectively. MM acknowledges support 
from the Medical Research Council. CRB and AAW acknowledge the support from the Dutch 
Heart Foundation (CVON PREDICT2 project to CRB, HLT and AAW) and the Netherlands 
Organization for Scientific Research (VICI fellowship, 016.150.610, to CRB). RT received 
support from the Philippa and Marvin Carsley Cardiology Chair, and is currently a clinical 
research scholar of the Fonds de Recherche du Québec – Santé. DJT, MJB and MJA are 
supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death 
Program. 
 
Disclosures: ERB received prior research funds from Biotronik and consulting for Medtronic. 
MJA reports involvement. AliveCor, Audentes Therapeutics, Blue Ox Health, Boston Scientific, 
Gilead Sciences, Invitae, Medtronic, MyoKardia, StemoniX, and St. Jude Medical. All others 
have none. 
 
References: 
 
1. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang C-E, 
Huikuri H, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and 
management of patients with inherited primary arrhythmia syndromes: document endorsed by 
HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. 
Heart Rhythm. 2013;10:1932–1963.  
 
2. Probst V, Wilde AAM, Barc J, Sacher F, Babuty D, Mabo P, Mansourati J, Le Scouarnec S, 
Kyndt F, Le Caignec C, et al. SCN5A mutations and the role of genetic background in the 
pathophysiology of Brugada syndrome. Circ Cardiovasc Genet. 2009;2:552–7.  
 
3. Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, Brugada P, Fressart V, 
Guerchicoff A, Harris-Kerr C, et al. An international compendium of mutations in the SCN5A-
encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart 
Rhythm. 2010;7:33–46.  
 
D
ow
nloaded from
 http://ahajournals.org by on N
ovem
ber 17, 2020
DOI: 10.1161/CIRCGEN.120.002911 
 
15 
This article is published in its accepted form; it has not been copyedited and has not appeared in an issue of the journal. 
Preparation for inclusion in an issue of Circulation: Genomic and Precision Medicine involves copyediting, typesetting, 
proofreading, and author review, which may lead to differences between this accepted version of the manuscript and the 
final, published version. 
4. Bezzina CR, Barc J, Mizusawa Y, Remme CA, Gourraud J-B, Simonet F, Verkerk AO, 
Schwartz PJ, Crotti L, Dagradi F, et al. Common variants at SCN5A-SCN10A and HEY2 are 
associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat 
Genet. 2013;45:1044–1049.  
 
5. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations 
in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart 
Rhythm. 2005;2:507–517.  
 
6. Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L, Schulze-Bahr E, Fukuhara S, 
Mochizuki N, Makiyama T, et al. The E1784K mutation in SCN5A is associated with mixed 
clinical phenotype of type 3 long QT syndrome. J Clin Invest. 2008;118:2219–29.  
 
7. Veltmann C, Barajas-Martinez H, Wolpert C, Borggrefe M, Schimpf R, Pfeiffer R, Cáceres G, 
Burashnikov E, Antzelevitch C, Hu D. Further Insights in the Most Common SCN5A Mutation 
Causing Overlapping Phenotype of Long QT Syndrome, Brugada Syndrome, and Conduction 
Defect. J Am Heart Assoc. 2016;5:pii: e003379.  
 
8. Schwartz PJ, Crotti L, George AL. Modifier genes for sudden cardiac death. Eur Heart J. 
2018;39:3925–3931.  
 
9. Baruteau A-E, Kyndt F, Behr ER, Vink AS, Lachaud M, Joong A, Schott J-J, Horie M, 
Denjoy I, Crotti L, et al. SCN5A mutations in 442 neonates and children: genotype-phenotype 
correlation and identification of higher-risk subgroups. Eur Heart J. 2018;39:2879–2887.  
 
10. Schwartz PJ, Gentilini D. Can genetics predict risk for sudden cardiac death? The relentless 
search for the Holy Grail. Eur Heart J. 2018;39:3970–3972.  
 
11. Hasdemir C, Payzin S, Kocabas U, Sahin H, Yildirim N, Alp A, Aydin M, Pfeiffer R, 
Burashnikov E, Wu Y, et al. High prevalence of concealed Brugada syndrome in patients with 
atrioventricular nodal reentrant tachycardia. Heart Rhythm. 2015;12:1584–94.  
 
12. Tadros R, Tan HL, ESCAPE-NET Investigators, El Mathari S, Kors JA, Postema PG, 
Lahrouchi N, Beekman L, Radivojkov-Blagojevic M, Amin AS, et al. Predicting cardiac 
electrical response to sodium-channel blockade and Brugada syndrome using polygenic risk 
scores. Eur Heart J. 2019;40:3097–3107.  
 
13. Antzelevitch C, Yan G-X, Ackerman MJ, Borggrefe M, Corrado D, Guo J, Gussak I, 
Hasdemir C, Horie M, Huikuri H, et al. J-Wave syndromes expert consensus conference report: 
Emerging concepts and gaps in knowledge. Heart Rhythm. 2016;13:e295-324.  
 
14. Priori SG, Pandit S V, Rivolta I, Berenfeld O, Ronchetti E, Dhamoon A, Napolitano C, 
Anumonwo J, di Barletta MR, Gudapakkam S, et al. A novel form of short QT syndrome (SQT3) 
is caused by a mutation in the KCNJ2 gene. Circ Res. 2005;96:800–807.  
 
15. Papadakis M, Papatheodorou E, Mellor G, Raju H, Bastiaenen R, Wijeyeratne Y, Wasim S, 
Ensam B, Finocchiaro G, Gray B, et al. The Diagnostic Yield of Brugada Syndrome After 
Sudden Death With Normal Autopsy. J Am Coll Cardiol. 2018;71:1204–1214.  
 
16. Bethesda (MD): National Center for Biotechnology Information NL of M. Database of 
Single Nucleotide Polymorphisms (dbSNP). dbSNP Build ID 151. [cited 2020 Sep 17]. 
Available from: https://www.ncbi.nlm.nih.gov/snp 
 
D
ow
nloaded from
 http://ahajournals.org by on N
ovem
ber 17, 2020
DOI: 10.1161/CIRCGEN.120.002911 
 
16 
This article is published in its accepted form; it has not been copyedited and has not appeared in an issue of the journal. 
Preparation for inclusion in an issue of Circulation: Genomic and Precision Medicine involves copyediting, typesetting, 
proofreading, and author review, which may lead to differences between this accepted version of the manuscript and the 
final, published version. 
Table 1. Clinical characteristics of (a) the total cohort broken down by genotype status; (b) 
comparing families harboring loss-of-function causing haploinsufficiency, other missense 
mutations and E1784K-SCN5A. 
a) 
  Total population, 
n=312 
SCN5A genotype 
positive, n=258 
SCN5A genotype 
negative, n=54 p-value 
n % n % N %  
Male 169 54 143 55 26 48 0.3603 
Caucasian 270 87 237 92 33 61 0.0015 
BrS 227 73 221 86 6 11 2.0E-16 
Spontaneous BrS ECG pattern * 88/201 44 88/196 45 0/5 0 2.0E-16 
Mutation type:  
     E1784K 103 33 79 31 24 44 0.2700† 
     LOF 79 25 62 24 17 31  
     Missense 130 42 117 45 13 24  
Quantitative variables 
 mean SD mean SD mean SD  
Age at ECG 38 17 39 17 35 16 0.3900 
PR interval 186 38 192 38 159 42 1.8E-12 
QRS duration 101 21 104 20 84 20 1.4E-09 
QTc interval 425 43 429 45 410 31 0.0064 
b) 
  Mutation type   
Loss-of-function 
causing 
haploinsufficiency 
n=62 
Missense (excluding 
SCN5A-E1784K) 
n=117 
SCN5A-E1784K                                         
n=79 p-value 
n % n % n %  
Male 44 71 68 58 31 39 0.0001 
Caucasian 62 100 117 100 58 73 2.0E-16 
BrS 59 95 105 90 57 72 0.0007 
Spontaneous BrS ECG pattern * 31/50 62 47/89 53 10/57 18 0.0011 
Quantitative variables 
 mean SD mean SD mean SD  
Age at ECG 36 16 44 15 33 17 0.0002 
PR interval 206 42 202 35 167 27 3.7E-13 
QRS duration 112 20 104 21 98 14 0.0003 
QTc interval 402 31 408 33 479 22 2.0E-16 
 
BrS = Brugada syndrome; QTc interval = QT interval corrected by Bazzett’s formula. * In 26 cases (25 genotype positive) 
specific data on the spontaneity of the type 1 pattern were missing. † overall p-value (chi-square test) testing the distribution of 
the three mutation types among SCN5A genotype positive vs. SCN5A genotype negative individuals. 
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Figure Legends: 
 
Figure 1. Flow diagram summarizing inclusion and numbers of individuals separated by 
genotype and BrS phenotype in each cohort. 
 
Figure 2. Risk of Brugada Syndrome in patients carrying an SCN5A mutation, Loss-of-function 
mutations causing haploinsufficiency, missense mutations other than SCN5A, and E1784K-
SCN5A. The odds ratio (OR) and 95% confidence interval for each mutation type are shown 
(adjusted for sex and age). The p-values denote the levels of significance of the odds ratios for 
Brugada Syndrome comparing each cohort to negative genotype using GEE. 
 
Figure 3. Cumulative number of risk alleles at the three loci and the associated likelihood of BrS 
phenotype showing performance of the BrS-GRS for prediction of BrS phenotype in mutation 
positive individuals in the (a) total cohort; (b) individuals from families harboring E1784K-
SCN5A); (c) individuals from families harboring loss-of-function SCN5A mutations causing 
haploinsufficiency; (d) other missense SCN5A mutations. Distribution of numbers of risk alleles 
hosted by individuals with BrS phenotype (black bars) in each cohort are shown vs family 
members ascertained to be BrS phenotype-negative (white bars). Each bar represents the 
proportion of individuals carrying the corresponding number of risk alleles as a percentage of the 
total number of individuals with the corresponding phenotype, i.e. denominator for the white 
bars being the total number of individuals with no BrS within the cohort, and the denominator 
for the black bars being the total number of individuals with BrS within the cohort. 
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Figure 4. Risk per additional risk allele in a linear model in the total cohort; genotype negative 
individuals; genotype positive individuals from families harboring loss-of-function mutations 
causing haploinsufficiency; genotype positive individuals from families harboring E1784K-
SCN5A; genotype positive individuals from families harboring other missense SCN5A mutations. 
The odds ratio (OR) per additional risk allele and 95% confidence interval are shown (adjusted 
for sex and age). The p-values denote the levels of significance of the odds ratios per additional 
risk allele for Brugada Syndrome in each cohort using GEE. The OR and 95%CI for Genotype 
positive: Loss-of-function causing haploinsufficiency cohort are not shown as these are off the 
scale of this figure.  
 
Figure 5. Risk of Brugada Syndrome in patients carrying ≥4 risk alleles in the total cohort; 
genotype negative individuals; genotype positive individuals from families harboring loss-of-
function mutations causing haploinsufficiency; genotype positive individuals from families 
harboring E1784K-SCN5A; genotype positive individuals from families harboring other 
missense SCN5A mutations. The odds ratio (OR) and 95% confidence interval for a cut off of ≥4 
risk alleles are shown (adjusted for age and sex). The p-values denote the level of significance of 
the odds ratios for this cut-off for Brugada Syndrome for each cohort using GEE. 
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